Benlysta (belimumab) — HCPCS J0490

Benlysta IV (J0490) vs Benlysta SC (pharmacy benefit) FDA verified May 2026

Two distinct billing pathways for the same molecule. Confirm which formulation the patient is on before submitting any claim.

GSK markets Benlysta in two formulations: the original intravenous Benlysta (J0490, since 2011) and the subcutaneous Benlysta (200 mg/mL prefilled syringe, FDA-approved July 2017; Benlysta autoinjector launched July 2017). The IV is a clinic-administered medical-benefit drug billed under HCPCS J0490. The SC is a patient-self-administered pharmacy-benefit drug dispensed through specialty pharmacy — not billed under J0490.

Lupus biologic class comparison ACR/EULAR + FDA labels May 2026

Where Benlysta sits in the lupus treatment landscape vs Saphnelo, off-label Rituxan, and Lupkynis.

Dosing & unit math FDA label verified May 2026

From the FDA prescribing information, most recent revision.

Adult IV (SLE + LN, ≥18 yr)

• Loading: 10 mg/kg IV over 1 hour at weeks 0, 2, and 4
• Maintenance: 10 mg/kg IV q4w thereafter
• ~3 loading doses + ~13 maintenance doses = ~16 doses in year 1; ~13 doses/year ongoing
• 1 unit = 10 mg, so a 700 mg dose (70 kg patient) = 70 units

Pediatric IV (SLE ≥5 yr, LN ≥5 yr)

• Same regimen as adult: 10 mg/kg IV at weeks 0, 2, 4, then q4w
• FDA-approved for SLE in pediatric patients ≥5 yr (April 2019)
• FDA-approved for active LN in pediatric patients ≥5 yr (July 2022)
• Bill the actual mg administered; weight-based dosing produces partial-vial waste — JW applies

Adult SC (pharmacy benefit, NOT J0490)

• SLE + LN: 200 mg SC weekly (no loading dose required)
• For SLE patients transitioning from IV to SC: first SC dose 1–4 weeks after the last IV dose
• For LN patients transitioning from IV to SC: 400 mg (two 200 mg injections) once weekly × 4 weeks, then 200 mg SC weekly
• Adults ≥18 yr only; not approved for pediatric use
• Dispensed through specialty pharmacy under pharmacy benefit; not billed under J0490

Worked example — first-year IV billing for a 70 kg adult SLE patient

Premedication

Not routinely required. Consider an antihistamine + acetaminophen for patients with prior infusion reactions. Hypersensitivity / infusion reactions can occur (W&P) — have IV access and emergency medications available during infusion.

NDC reference FDA NDC Directory verified May 2026

Lupus nephritis indication FDA verified May 2026

FDA approval Dec 2020 (adult LN) and Jul 2022 (pediatric LN ≥5 yr) — Benlysta is the first biologic with on-label active LN coverage.

On December 17, 2020, the FDA approved Benlysta as the first treatment specifically indicated for active lupus nephritis — covering both the IV and SC formulations in adults. In July 2022, the FDA expanded the IV LN indication to pediatric patients aged 5 years and older, making Benlysta the only biologic with both adult and pediatric LN labeling.

Billing requirements specific to LN

• Primary ICD-10: M32.14 — "Glomerular disease in systemic lupus erythematosus"
• Supplementary codes: N-codes for kidney findings (e.g., N04.x nephrotic syndrome, N18.x CKD stage, N06.x isolated proteinuria with specified morphologic lesions) as documented
• Add-on positioning: Benlysta is added to standard LN therapy (mycophenolate or cyclophosphamide induction; mycophenolate or azathioprine maintenance) plus corticosteroids, NOT used as monotherapy
• Trial reference: BLISS-LN (Phase 3, 448 patients with biopsy-confirmed active LN class III/IV/V; primary endpoint was Primary Efficacy Renal Response at week 104)

Why the LN indication matters for billing

• Saphnelo (J0491) is excluded from active LN. Anifrolumab's label specifically states it has not been studied in patients with severe active lupus nephritis or severe active CNS lupus — payers commonly enforce this exclusion in PA criteria.
• Lupkynis is oral and adult-only. Voclosporin (Lupkynis) is an oral CNI approved for adult LN in 2021, but it does not address the biologic medical-benefit pathway.
• Rituxan is off-label for LN. Some payers cover rituximab for refractory LN per NCCN/EULAR guideline pathways, but it is not FDA-approved.

Pediatric (≥5 yr) indication FDA verified May 2026

Only labeled biologic for pediatric SLE and pediatric active LN — FDA approvals 2019 and 2022.

On April 26, 2019, the FDA approved Benlysta IV for pediatric patients aged 5 years and older with active, autoantibody-positive SLE who are receiving standard therapy — the first biologic ever approved for pediatric lupus. On July 27, 2022, the FDA expanded Benlysta IV to pediatric active LN in patients aged 5 years and older, again the first labeled pediatric LN biologic.

Pediatric billing essentials

• IV only. The SC formulation is approved only for adults ≥18 yr.
• Same regimen as adults: 10 mg/kg IV at weeks 0, 2, 4, then q4w
• Weight-based dosing → partial-vial waste is the norm. JW modifier applies on most pediatric claims; document the math.
• Site of care: Pediatric infusion suite (POS 11 or 49); some health systems run dedicated pediatric rheumatology infusion programs
• No premedication routinely required; standard pediatric infusion-reaction precautions

Why this is uniquely valuable for pediatric rheumatology

The other lupus biologics — Saphnelo (anifrolumab), Rituxan (rituximab, off-label for SLE), and Lupkynis (voclosporin) — have no pediatric labeling. For a pediatric patient with refractory SLE or active LN on standard therapy, Benlysta is the only on-label biologic option, and IV is the only approved route. Pediatric rheumatology practices billing J0490 carry an outsized share of all pediatric lupus biologic claims.

Administration codes CPT verified May 2026

Belimumab is a non-chemo monoclonal antibody — use therapeutic IV admin codes, NOT chemo admin.

Modifiers CMS verified May 2026

JW — the typical modifier for Benlysta

Benlysta is supplied in fixed 120 mg and 400 mg single-dose vials, but dosing is weight-based (10 mg/kg). Most patients require a combination of vials that produces partial-vial waste. JW reports the discarded units on a separate claim line. Example: 70 kg patient receives 700 mg; pharmacy reconstitutes 1 × 400 mg + 3 × 120 mg = 760 mg drawn, 700 mg administered, 60 mg discarded. Bill 70 units of J0490 (administered) + 6 units with JW (discarded).

JZ — only when the math lines up exactly

JZ reports zero discarded drug from a single-dose container. For Benlysta, JZ applies only when the calculated dose exactly matches a whole-vial combination — uncommon with weight-based dosing. Example: a 60 kg patient receives exactly 600 mg = 1 × 400 mg + 1 × 200 mg (which doesn't exist as a vial size, so this scenario reduces to 1 × 400 mg + 2 × 100 mg — not a vial size either; 600 mg is achievable as 5 × 120 mg = 600 mg, JZ applies). Document the math clearly.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (e.g., new-symptom assessment, dose adjustment review, related ROS). Routine pre-infusion clinical assessment is bundled into the infusion service.

340B modifiers (JG, TB)

For 340B-acquired Benlysta, follow your MAC's current 340B modifier policy. Hospital outpatient and FQHC sites participating in 340B should include the appropriate modifier per the 2026 OPPS rules.

ICD-10-CM by indication FY2026 verified May 2026

Use the most specific code supported by the encounter documentation. M32.14 is the primary code for active LN.

Common supplementary codes for LN claims

Site of care & place of service Verified May 2026

UnitedHealthcare and Aetna increasingly enforce site-of-care UM for chronic biologic infusions including Benlysta. Both prefer office or ambulatory infusion suite over hospital outpatient after the patient is stable on therapy.

Claim form field mapping GSK 2026 + CMS verified May 2026

Standard CMS-1500 fields for J0490. Confirm payer-specific requirements (e.g., 340B modifier placement).

Payer policy snapshot Reviewed May 2026

All major payers require PA, SLE/LN diagnosis, and standard-therapy failure documentation.

Standard therapy expected before Benlysta

• SLE: hydroxychloroquine + corticosteroids; many payers also require an immunosuppressant (azathioprine, methotrexate, MMF) trial
• LN: standard induction (mycophenolate or cyclophosphamide) + corticosteroids; Benlysta is added on, not substituted
• Document the duration of trial, response, and reason for adding Benlysta

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

No NCD specific to belimumab. Coverage falls under MAC LCDs for biologics + the generic drug coverage framework. All MACs cover J0490 for FDA-approved on-label indications (SLE in adults + peds ≥5 yr; active LN in adults + peds ≥5 yr) with appropriate ICD-10 documentation and standard-therapy history.

Code history

• J0490 — permanent code, "Injection, belimumab, 10 mg" (1 unit = 10 mg). Pre-permanent-code period used unclassified J3490.

Patient assistance — GSK For You / Bridges to Access GSK verified May 2026

• GSK For You / Benlysta Co-pay Card: commercial copay support — eligible commercially-insured patients pay as little as $0 for the first dose, with ongoing copay support up to $20,000/year (excludes Medicare, Medicaid, federal program patients)
• GSK Bridges to Access (Patient Assistance Program): free Benlysta for uninsured / underinsured patients meeting income requirements
• GSK Reimbursement Support: benefits investigation, prior authorization assistance, appeal support, denial management
• Phone: 1-844-468-2225 (1-844-GSK-2BCK)
• Foundations for Medicare patients: refer to PAN Foundation, HealthWell Foundation, Patient Advocate Foundation — verify open lupus / autoimmune funds quarterly
• Web: benlysta.com / gskforyou.com

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Benlysta?

Benlysta IV is billed under HCPCS J0490 — "Injection, belimumab, 10 mg." One unit equals 10 mg, so a 700 mg dose (70 kg patient × 10 mg/kg) is billed as 70 units. J0490 only covers the IV formulation under the medical benefit. The subcutaneous Benlysta (200 mg/mL prefilled syringe and Benlysta autoinjector) is a pharmacy-benefit product that the patient self-administers at home — it is NOT billed under J0490.

How is Benlysta dosed for SLE and lupus nephritis?

Both SLE and active lupus nephritis (LN) use the same IV regimen: 10 mg/kg over 1 hour at weeks 0, 2, and 4 (loading), then 10 mg/kg every 4 weeks (maintenance). The IV regimen is approved for adults and pediatric patients aged 5 years and older. The SC formulation (200 mg weekly self-injection) is approved only for adults aged 18 years and older with SLE or LN, and is dispensed through specialty pharmacy under the pharmacy benefit.

What administration CPT codes do I use for Benlysta IV?

96365 — "Therapeutic IV infusion, up to 1 hour, initial substance/drug." Use 96366 if the infusion runs beyond 1 hour. Belimumab is a monoclonal antibody but is NOT classified as chemotherapy administration, so do not bill 96413.

Do I bill JZ or JW for Benlysta?

Benlysta is supplied as 120 mg and 400 mg single-dose vials, and weight-based dosing (10 mg/kg) almost always produces partial-vial waste. Bill JW with the discarded units when partial vials are wasted (the typical scenario). Bill JZ only when the calculated dose exactly matches whole vial combinations. One of JZ or JW must appear on every J0490 claim per CMS's July 2023 single-dose container policy.

What is the Medicare reimbursement for J0490?

For Q2 2026, the Medicare Part B payment limit for J0490 is $57.189 per unit (per 10 mg), ASP + 6%. A 70 kg patient receiving 700 mg (70 units) reimburses at approximately $4,003.23 per dose; an 80 kg patient at 800 mg (80 units) at approximately $4,575.12. Annualized maintenance cost (~13 doses/year q4w) for a 70 kg patient: roughly $52,000. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.

Does Benlysta cover lupus nephritis?

Yes. The FDA approved Benlysta for active lupus nephritis (LN) in adults in December 2020 and extended the LN indication to pediatric patients aged 5 years and older in July 2022. This is a key billing distinction from Saphnelo (anifrolumab, J0491), which is approved only for SLE without active LN. For LN, use ICD-10 M32.14 (SLE with glomerular disease) plus appropriate N-codes for kidney findings. Benlysta is added to standard LN therapy (mycophenolate or cyclophosphamide induction; mycophenolate or azathioprine maintenance) plus corticosteroids.

Is Benlysta approved for pediatric patients?

Yes — Benlysta is the only FDA-approved biologic for pediatric lupus. The IV formulation is approved for pediatric SLE patients aged 5 years and older (FDA approval April 2019) and for pediatric LN patients aged 5 years and older (FDA approval July 2022). Pediatric dosing matches adult: 10 mg/kg IV at weeks 0, 2, 4, then every 4 weeks. The SC formulation is NOT approved for pediatric use. Saphnelo, Rituxan (off-label for SLE), and Lupkynis are not approved for pediatric lupus, making Benlysta the only labeled biologic option for pediatric rheumatology.

How does Benlysta compare to Saphnelo and Rituxan for lupus?

Benlysta (belimumab, J0490) is an anti-BAFF mAb — first FDA-approved biologic for SLE (2011), pediatric SLE (2019), and active LN (2020/2022). Saphnelo (anifrolumab, J0491) is an anti-type-I-interferon-receptor mAb approved for SLE in adults (2021) but NOT for active LN or pediatric use. Rituxan (rituximab, J9312) is anti-CD20 — used off-label for refractory SLE with neuropsychiatric or hematologic manifestations; not FDA-approved for SLE. Lupkynis (voclosporin) is an oral calcineurin inhibitor for adult LN. For pediatric SLE and LN, Benlysta is the only labeled biologic option. See the class comparison table.

Source documents

1. DailyMed / FDA — BENLYSTA (belimumab) Prescribing Information
   FDA-approved label, includes 2020 LN expansion and 2022 pediatric LN expansion (BLA 125370)
2. FDA Press Announcement — First treatment for pediatric lupus (April 2019)
3. FDA Press Announcement — First treatment for adult lupus nephritis (December 2020)
4. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
5. GSK — Benlysta HCP page (coding, coverage, reimbursement)
6. GSK For You — Patient Assistance · Co-pay Card · Bridges to Access
   1-844-468-2225 (1-844-GSK-2BCK)
7. UnitedHealthcare — Belimumab (Benlysta) Medical Drug Coverage Policy
8. Aetna — CPB on Belimumab (Benlysta) coverage policy
9. ACR — SLE management guidelines
10. EULAR — SLE / lupus nephritis recommendations (2024 update)
11. FDA National Drug Code Directory
12. SEER CanMED — HCPCS J0490 reference

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication. ASP data: Q2 2026. Manufacturer source: GSK 2026. FDA label: most recent revision (incl. Dec 2020 adult LN + Jul 2022 pediatric LN expansions). Lupus biologic class comparison vs Saphnelo, Rituxan (off-label), Lupkynis included. IV (J0490) vs SC (pharmacy benefit) distinction documented.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical / pharmacy policy documents. Indication list is verified against the current FDA label revision. We do not paraphrase from billing-software vendor blogs.